SMi Group reports: CTO and Co-Founder of Envisagenics, Martin Akerman discusses the challenges and developments in the RNA industry SMi’s 13th Annual RNA Therapeutics Conference will welcome expert speakers from big pharma companies to bring […]
SMi Group reports: Co-Chairs, Philip Hewitt and Stefan Pryzyborski for SMi’s 5th Annual 3D Cell Culture invite industry professionals to join the conference in February 2022. Philip Hewitt, Global Head of Early Investigative Toxicology, Merck […]
SMi Reports: Agenda and speaker overview of the upcoming 5th Annual 3D Cell Culture Conference. SMi Group is delighted to announce the return of the successful 3D Cell Culture Conference for its 5th year, taking […]
Gritstone bio and the Coalition for Epidemic Preparedness Innovations have expanded their agreement to develop a self-amplifying mRNA vaccine against the Omicron variant of the SARS-CoV-2 virus. SAM vaccines leverage the machinery of the body […]
AstraZeneca and Ionis Pharmaceuticals have signed an agreement to develop and market experimental therapy, eplontersen, previously called IONIS-TTR-LRX. Eplontersen is a ligand-conjugated antisense treatment that can potentially lower the transthyretin (TTR protein) production for treating […]